Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

NCT06093503 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Strategic considerations

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Telisotuzumab Vedotin
DRUG: Osimertinib
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

AbbVie